CytoSorbents to Present at H.C. Wainwright Investment Conference
CytoSorbents Corporation (NASDAQ: CTSO) will participate in the H.C. Wainwright 28th Annual Global Investment Conference, scheduled for September 14–16, 2026, in New York City. The company's CEO and CFO are set to join a fireside chat with an equity research analyst from H.C. Wainwright as well as engage in one-on-one meetings with investors. CytoSorbents is focused on blood purification technologies for treating life-threatening conditions such as sepsis, trauma, liver failure, and cytokine storms using its lead product CytoSorb®. The device has received regulatory approvals in the European Union but remains under FDA Emergency Use Authorization in the U.S., specifically for adult critically ill COVID-19 patients.
